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Abstract
Brain metastases (BM) are most common intracranial tumors in adults. Recently, signifi-
cant progress has been shown in diagnosing, prognosis, and treating patients with BM of 
various malignant tumors. The treatment decisions must be based on the disease progno-
sis and include radiation therapy, surgery, systemic antitumor therapy, or a combination 
thereof. Systemic therapy capable of preventing BM or which affects both intracranial 
and extracranial disease is of paramount importance in the treatment of BM patients. The 
purpose of this chapter is to consider important prognostic factors that can determine 
treatment decisions, review the role of blood–brain barrier (BBB), and systemic anticancer 
treatment to manage BM from solid tumors.
Keywords: brain metastases, solid tumors, prognostic scores, blood–brain barrier, 
systemic anticancer treatment
1. Introduction
Brain tumors constitute for 85–90% of all tumors of the central nervous system (CNS) [1]. Brain 
metastases (BM) are ten times more prevalent than primary tumors of the central nervous sys-
tem (CNS) and are diagnosed in 10–20% of all cancer patients. The frequency of detection of 
BM is steadily increasing, which can be explained by such causes. First, this may be due to the 
increased availability and improvement of diagnostic methods for brain tumors. Second, the 
use of screening brain examinations of patients with tumors has a high incidence of the CNS 
metastases. Third, the improved effectiveness of anticancer treatment leads to increased over-
all survival rates of patients and increased risk of developing BM [2]. All malignant tumors 
have the potential to provide distant metastasis to the brain. Approximately 75% of all cases 
of brain metastases are due to patients with lung cancer (40–50%), breast cancer (15–25%), 
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and melanoma (5–20%) [1]. Among the remaining 25%, BM is more predominant in patients 
with renal cell cancer (4–17%) and gastrointestinal cancer (0.6–3%) [3, 4]. At autopsy, BM are 
found to be 1.5–3 times more frequent and are detected in more than 65% of patients with lung 
cancer, 30–40% of patients with malignant melanoma (MM), and 30% of patients with breast 
cancer (BC). About 85% of metastatic lesions are located in the brain hemispheres, 15% in the 
cerebellum, and 5% in the brain stem [5].
The aim of this review is to consider important prognostic factors that can determine the treat-
ment decisions and to review the role of blood–brain barrier (BBB) and systemic anticancer 
treatment (SAT) to manage BM from solid tumors.
2. Determination of prognosis of patients with brain metastases
The BM patients have significantly worsened the prognosis because the median overall sur-
vival (OS) in BM cases varies from 2.79 to 25.3 months. The disease prognosis depends on 
a number of factors that must be taken into account when determining the treatment algo-
rithm of patients with BM. Table 1 presents prognostic scales assessment of the prognosis in 
patients with cerebral metastases [6].
Table 1 presents the assessment scales of the overall survival prognosis of brain metastases 
patients have a number of limitations who restrict their use in routine clinical practice and 
clinical trials. The Recursive partitioning analysis (RPA) scale can be used only if the patient 
is shown to be carrying out the whole brain radiotherapy (WBRT). RPA cannot be used on 
patients who underwent palliative surgery, stereotactic radiosurgery (SRS), and/or systemic 
anticancer therapy, but this treatment option has significant effect on BM patient’s survival. 
Another limiting factor of the RPA score system is that it does not take into account the size 
and number of BM. The drawbacks of the Rotterdam score system are the lack of consideration 
of the patient’s age, number, and size of BM. The most complete predictive system is the Score 
Prognostic factors RPA Rotterdam score SIR BSBM GPA DS-GPA
Age + — + — + +
Performance status KPS ECOG KPS KPS KPS KPS
Extracranial metastases + + + + + +
Control of primary tumor + — + + — —
Number of BM — — + — + +
Volume of BM — — + — — —
Response to steroids — + — — — —
Number of classes 3 3 3 4 4 4
RPA: Recursive partitioning analysis; SIR: Score Index for Radiosurgery; BSBM: Basic Score for Brain Metastases; GPA: 
Graded Prognostic Assessment; DS-GPA: Disease specific Graded Prognostic Assessment; KPS: Karnofsky performance 
status; ECOG: Eastern Cooperative Oncology Group Score.
Table 1. Prognostic scores for brain metastasis patients.
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Index for Radiosurgery (SIR) scale, but it has not been widely used in clinical practice since it 
does not take into account systemic influence to disease. The Basic Score for Brain Metastases 
(BSBM) scale is an analogue of RPA scale and takes into account the impact of SRS on the 
survival of BM patients, but it does not take into account the patient’s age and the effective-
ness of systemic drug therapy. In 2007, the Graded Prognostic Assessment (GPA) scoring sys-
tem was proposed, which took into account four factors: age, Karnofsky performance status 
(KPS), availability of extracranial metastases, and the number of BM. A number of studies have 
proved the prognostic significance of these indicators, and the GPA scale is recognized as the 
most objective and most commonly used scoring system for survival prognosis of BM patients. 
However, GPA system does not consider the influence of primary tumor type for prognosis of 
BM, which has different sensitivity to the drug and radiation therapy. To account the influence 
of the prognostic value of the histological and molecular type of the primary tumor, a Disease 
Specific Graded Prognostic Assessment (DS-GPA) system was developed. Table 2 presents the 
factors and prognosis of overall survival rates of patients with BM from lung cancer, MM, BC, 
renal cell (RCC), and gastrointestinal cancer (GI) [7].
Prognostic factor GPA scale score Total 
score
Median of overall 
survival, months (95% 
СІ)
0 0.5 1.0 — —
Lung cancer
Age (years) >60 50–60 < 50 — — NSCLC SCLC
KPS <70 70–80 90–100 — — 0–1 3.02 
(2.63–3.84)
2.79 
(1.83–3.12)
Extracranial metastases Yes n/a No — — 1.5–2.0 5.49 
(4.83–6.40)
4.90 
(4.04–6.51)
— — 2.5–3.0 9.43 
(8.38–10.80)
7.67 
(6.27–9.13)
Number of BM > 3 2–3 1 — — 3.5–4.0 14.78 
(11.80–
18.80)
17.05 
(4.70–27.43)
Malignant melanoma
Prognostic factor GPA scale score Total 
score
Median of overall 
survival, months (95% 
СІ)0 1.0 2.0 — —
KPS <70 70–80 90–100 — — 0–1 3.38 (2.53–4.27)
Number of BM >3 2–3 1 — — 1.5–2.0 4.7 (4.07–5.39)
2.5–3.0 8.77 (6.74–10.77)
3.5–4.0 13.23 (9.13–15.64)
Breast cancer
Prognostic factor GPA scale score Total 
score
Median of overall 
survival, months (95% 
СІ)0 0.5 1.0 1.5 2.0
Age (years) ≥ 60 < 60 — — — 0–1 3.35 (3.13–3.78)
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Prognostic factor GPA scale score Total 
score
Median of overall 
survival, months (95% 
СІ)
0 0.5 1.0 — —
KPS ≤ 50 60 70–80 90–100 — 1.5–2.0 7.70 (5.62–8.74)
Molecular type Triple 
negative
— Lum A HER2-
type
Lum В 2.5–3.0 15.07 (12.94–15.87)
3.5–4.0 25.30 (23.10–26.51)
Renal cell cancer
Prognostic factor GPA scale score Total 
score
Median of overall 
survival, months (95% 
СІ)0 1.0 2.0 — —
KPS <70 70–80 90–100 0–1 3.27 (2.04–5.10)
Number of BM >3 2–3 1 1.5–2.0 7.29 (3.73–10.91)
2.5–3.0 11.27 (8.80–14.80)
3.5–4.0 14.77 (9.73–19.79)
Gastrointestinal cancer
Prognostic factor GPA scale score Total 
score
Median of overall 
survival, months (95% 
СІ)0 1.0 2.0 3.0 4.0
KPS < 70 70 80 90 100 0–1 3.13 (2.37–4.57)
1.5–2.0 4.40 (3.37–6.53)
2.5–3.0 6.87 (4.86–11.63)
3.5–4.0 13.54 (9.76–27.12)
NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; KPS: Karnofsky performance status; n/a: not applicable; 
ER: estrogen receptors; PR: progesterone receptors; Her2/neu (ErbB2): human epidermal growth factor receptor 2; Triple 
negative: ER-negative, PR-negative, Her2/neu-negative; Lum A: ER-positive and/or PR-positive, Her2/neu-negative; 
HER2-type: ER-negative, PR-negative, Her2/neu-overexpression/amplification; Lum В: ER-positive and/or PR-positive, 
Her2/neu-overexpression/amplification.
Table 2. Median of overall patient survival with BM from solid tumors according to the DS-GPA scale prognosis indices.
Prognostic scores are very important to take decisions on the most appropriate treatment 
options for patients with BM in each case. The need for palliative treatment for patients with 
poor prognosis is controversial, but patients with good prognosis must receive multidisciplinary 
palliative therapy to increase overall survival rates [8]. Moreover, prognostic score systems can 
be used to increase the applicability, objectivity, and validity of the clinical trial results that 
investigate the effectiveness of treatment in patients with BM from various malignant tumors.
3. Role of the blood-brain barrier in the formation of brain 
metastases
The blood-brain barrier (BBB) plays a prominent role in the brain colonization by malignant 
tumor cells and determines the effectiveness of drug therapy. BBB is a natural obstacle for the 
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penetration of malignant tumor cells within the brain parenchyma. Endothelial cells of brain 
vessels serve as a mechanical barrier, and astrocytes and microglia are capable of destroying 
tumor cells. However, after brain colonization, the cerebral endothelial cells, astrocytes, and 
microglia provide crucial support in the growth and proliferation of tumor cells, and BBB 
protects cancer cells from influencing the immune system and most anticancer drugs [9].
The penetration of the BBB depends on its functional condition, as well as on the morphologi-
cal, molecular, and genetic characteristics of tumor cells, that may explain the opportunity of 
some malignant cells to easily overcome this highly selective barrier relatively. For example, the 
compound density reduction of the cerebral endothelial cells, which increase the permeability 
of BBB, was detected in severe CNS diseases such as Alzheimer’s disease, multiple sclerosis, and 
primary and metastatic brain tumors [10]. The expression CDH2 (N-cadherin), KIFC1, and FALZ 
genes in a primary tumor in lung cancer patients with BM determine the high cerebral metastatic 
potential of lung cancer cells. The CDH2 gene encoded N-cadherin (cadherin-2 or neural cad-
herin (NCAD)) is involved in tumor progression, such as migration and invasion of tumor cells, 
including in the CNS. Also, in non-small cell lung cancer, patients’ expression of DCUN1D1 
squamous cell carcinoma-associated oncogene may promote the tumor cell migration through 
the BBB and development of BM. High KLF6-SV1 expression in prostate cancer cells associated 
with poor patient’s survival predict a high risk of lymph nodes, brain, and bones metastasis 
[11]. Several factors have been identified in breast cancer cells that promote the BC cell migra-
tion through the BBB, such as cyclooxygenase-2 (COX2), heparin-binding epidermal growth 
factor-like growth factor (HB-EGF), and ST6GALNAC5 ((alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide-alpha-2,6-sialyltransferase 5 ST6). The ST6GALNAC5 
gene expression is recognized as a tumor cells BBB migration specific marker because COX2 and 
HB-EGF are associated with the brain and lung metastases. In vitro studies of melanoma cells 
were shown to increase the BBB permeability by reduce transendothelial electrical resistance of 
endothelial cells. Expression of melanotransferrin (MELTF, CD228, MAP97, MTF1, MTf, MFI2) 
and signal transducer and transcriptional activator 3 (STAT3) can serve as potential markers of 
cerebral metastases in patients with melanoma. The availability of MELTF on the melanoma cell 
membrane determines their ability to penetrate through the BBB. High levels of STAT3 in mela-
noma BM compared to primary tumor cells indicate a relationship between STAT3 expression 
and tumor cell migration to the brain [9]. Thus, the identification of tumor cells specific markers 
of penetration through the BBB can be a basis for the development of specific methods for the 
prevention of BM. The main factor of the BM treatment resistance is BBB efflux transporters 
which prevent the drug’s penetration into the brain parenchyma. Table 3 shows the main drug 
efflux transporters of the BBB and their substrates and inhibitors [12].
P-glycoprotein (Pgp, gp170) is a protein encoded by the gene MDR1 (multidrug resistance 1) 
whose main function is the active removal of many different substances, including some 
drugs, from the cell cytoplasm to the intercellular environment. Pgp molecules are found in 
the proximity of the apical membrane of the choroid plexus secretory cells and at the luminal 
membrane of the brain capillary, which allows transferring most of the Pgp substrates from 
the endothelium and parenchyma of the BM to the cerebrospinal fluid and blood. The role 
of Pgp in the maintenance of BBB was investigated through in vivo studies. Studies con-
ducted on MDR1 gene knockout mice revealed an increased effect on brain parenchyma of 
parenterally administered P-glycoprotein substrates compared with wild-type mice. The use 
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of  Pgp-inhibitors in wild-type animals was accompanied by an increase in the brain penetra-
tion of Pgp substrates including anticancer drugs (vincristine, paclitaxel, daunorubicin, etc.). 
Similar results were obtained on using P-glycoprotein inhibitors (verapamil and cyclosporin 
A) to increase the BBB penetration [7].
Multidrug resistance-associated proteins (MRP) are the ABCC family of transporter (ATP-binding 
cassette subfamily C) proteins, which are an important component determining the selective 
permeability of the BBB for different drugs [13]. In vivo studies performed on mice with 
knockout of the MRP1 gene were found to have higher accumulation of MRP1 substrates, 
including etoposide versus wild-type mice. And after the use of the inhibitor MRP1 (proben-
ecid), a double increase in the concentration of fluorescein in the brain was observed [7].
Breast cancer-resistant protein (BCRP, ABCG2). ABCG2 (ATP-binding cassette subfamily G 
member 2) is an efflux transporter called the breast cancer resistance protein, since it was first 
detected in the drug-resistant MCF-7 human breast cancer cells [14]. BCRP is an important 
component in determining BBB permeability, and its concentration in the CNS endothelium is 
greater than the P-glycoprotein and MRP1 concentrations. In mice with BCRP1 gene knockout, 
the imatinib concentration in the brain parenchyma was increased 2.5-fold in knockout versus 
control mice. The administration of a BCRP inhibitor (elacridar) in wild-type mice results in an 
increase in the penetration of imatinib 4.2 times, while in knockout MDR1 gene mice, elacridar 
increases cerebral cells absorption of BCRP substrates such as prazosin and mitoxantrone [15].
The structure of BBB in brain metastatic tumors has some features. In contrast to the normal 
cerebral vascular network, the brain metastases have an increased perivascular space, number, 
and activity of pinocytotic vacuoles in endothelial cells; these features are more typical for tumor 
vessels than for the CNS vessels. Thus, metastatic tumor BBB is more permeable than in the 
normal CNS parenchyma and is more likely to be a capillary barrier than a performed BBB [7].
Efflux transporter Substrates Inhibitors
P-glycoprotein Doxorubicin, daunorubicin, docetaxel, 
paclitaxel, epirubicin, idarubicin, 
vinblastine, vincristine, etoposide
Verapamil, cyclosporine A, quinidine, valspodar, 
elacridar, biricodar, zosuquidar, tariquidar
MRP1 Etoposide, teniposide, daunorubicin, 
doxorubicin, epirubicin, melphalan, 
vincristine, vinblastine
Probenecid, sulfinpyrazone, MK-571, cyclosporin 
A, verapamil, valspodar
MRP2 Probenecid, MK-571, leukotriene C4
MRP3 Sulfinpyrazone, indomethacin, probenecid
MRP4 Methotrexate, 6-mercaptopurine, 
thioguanine
Probenecid
MRP5 6-Mercaptopurine, thioguanine Probenecid, sildenafil
MRP6 Actinomycin D, cisplatin, daunorubicin, 
doxorubicin, etoposide
Probenecid, indomethacin
BCRP Mitoxantrone, methotrexate, SN-38, 
topotecan, imatinib, erlotinib, gefitinib
Elacridar, fumitremorgin C
Table 3. Substrates and inhibitors of the main drug efflux transporters of the BBB.
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3.1. Influence of radiation therapy on the BBB permeability
Brain radiotherapy is the standard of palliative care as per the guidelines of clinical prac-
tice for patients with BM. In several in vivo studies in rats after brain radiation were such 
changes observed: dilation and thickening of the blood vessel wall, increase of endothelial 
cell nuclei, astrocyte hypertrophy, and 60% decrease the P- glycoprotein concentration [7]. 
These changes in the brain of rats were a prerequisite for a hypothesis about influence of 
radiation to the BBB permeability and increase in the clinical effectiveness of chemotherapy 
in patients with BM, because radiation could raise the penetration of anticancer drugs into 
the brain parenchyma. Murrell D.H., et al. (2016) did not found changes in BBB permeability 
at the 1st and 11th days after radiation in mice after WBRT therapeutically relevant doses 
to human equivalent doses. The results of clinical studies have not revealed an increase in 
clinical effectiveness in the concurrent use of radiation and chemotherapy [16]. The BBB 
permeability modification under the influence of radiation on the BM at the moment is con-
troversial and needs further study.
3.2. Increasing of drug’s penetrations through the BBB
The ideal compound to treat BM must have the following physicochemical properties such as low 
molecular weight, lipophilicity, and absence of ionization at physiological pH. Physicochemical 
properties of most anticancer drugs not match the above specifications, that limit BBB perme-
ability of drugs, and was a basis for developing ways to deliver drugs to the brain. There are 
several ways to improve the delivery of substances to the central nervous system, for exam-
ple, the BBB opening under conditions of temporary osmotic shock, the use of chemical vec-
tors (transporters), increasing the dose and the frequency of drug administration, the use of 
implants from biodegradable materials, and so on. All methods of increasing drug delivery to 
the CNS can be attributed to one or more of the three main approaches: change in the chemical 
structure and/or physicochemical properties, and/or drug dose (concentration), increasing the 
BBB permeability, and using alternative routes of administration. The low efficiency of most 
approaches, with the need for performing technically complex manipulations that are accom-
panied by pronounced side effects and complications, limits their use in everyday clinical prac-
tice [17].
The most available methods for improving the drug delivery to BM in routine clinical prac-
tice are the use of nanoparticles and efflux transporters inhibitors (Table 3). Application of 
nanoparticles for targeted drug delivery has several advantages: overcoming chemoresis-
tance, increasing the drug bioavailability and specificity, dose reduction without loss of effi-
cacy, and reduction in adverse reactions. The clinical studies performed on the effectiveness 
of the nanoparticle application with anticancer drugs served as a basis for the use of these 
drugs as standard therapy for BM patients. Table 4 shows chemotherapeutic drugs with 
nanoparticles, the use of which has been approved by the US Food and Drug Administration 
(FDA) for the treatment BM patients [18].
The clinical trial results of the efficacy of anticancer nanomedicines and efflux transporter 
inhibitors in BM patients are encouraging, but further trials are needed to study biodistribu-
tion, pharmacokinetics, toxicity, and side effects for inclusion of this drug practice guidelines 
for the management of CNS tumors.
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Type of palliative treatment Indications
Systemic anticancer therapy - BM from systemic anticancer therapy-sensitive primary tumor;
- Asymptomatic BM, detected during planning of systemic anticancer therapy;
- BM from PT with identified molecular alteration amenable to targeted therapy;
- Poor effect of other treatment options in case presence of potentially effective 
systemic anticancer agents.
Whole brain radiotherapy - Multiple MGM (> 3–10), especially if the primary tumor is sensitive to radiation 
therapy;
- Large (4 cm) BM;
- After surgical resection of a dominant large metastatic tumor and the presence of 
multiple BM (> 3–10);
- BM disease progression during systemic drug therapy;
- Salvage therapy for recurrent BM after SRS or WBRT failure.
SRS - Oligo-BM or multi-BM (≤3), especially if primary tumor is known to be 
radiotherapy resistant;
- After surgical resection of a single BM if it diameter > 3 cm and/or BM localized in 
the posterior cranial fossa;
- Local recurrence after surgical resection of a single BM;
- Salvage therapy for recurrent oligo-BM or multi-BM (≤ 3) after WBRT failure.
4. Decision-making of palliative care options of BM patients
The decision-making of BM patient’s treatment must rely on some factors such as: the patient 
Karnofsky performance status; the number, size, and location of BM; the primary tumor type; 
and the presence and control of extracranial metastases. Table 5 presents palliative treatment 
options of BM patients depending on the set of predictive factors listed above [7].
Name Description Indication
DaunoXome Liposomal daunorubicin First-line therapy against advanced 
Kaposi’s sarcoma associated with HIV
DepoCyt Liposomal cytarabine Lymphomatous meningitis
Oncaspar L-asparaginase conjugated with 
monomethoxypolyethylene glycol (mPEG)
Acute lymphoblastic leukemia
Abraxane Albumin-bound paclitaxel nanospheres Pancreatic cancer, NSCLC, breast 
cancer
Myocet Liposomal doxorubicin Breast cancer
Marqibo Liposomal vincristine Acute lymphoblastic leukemia
Genexol Paclitaxel-loaded polymeric micelle Breast cancer, NSCLC, ovarian cancer
Onivyde Liposomal irinotecan Pancreatic cancer
Table 4. Anticancer nanomedicines approved by the FDA.
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According to Table 5, patients with brain metastases are not receiving anticancer therapy only 
if they have progression of the disease after receiving several types of anticancer therapy and 
them performance status stay poor after adequate supportive care [19].
5. Systemic anticancer therapy for BM patients
The evidence of the effectiveness of systemic anticancer therapy in patients with BM is con-
tradictory. Nevertheless, SAСT may be an effective treatment option for patients with BM, 
because it prolongs overall survival, especially in patients with metastatic lesions in other 
organs, since the progression of extracranial metastases is a common cause of death of most 
patients [20]. The BBB is a natural barrier for most anticancer drugs, and it is the primary 
mechanism responsible for BM resistance to systemic therapy. Several retrospective clinical 
studies determined that the chemotherapy was effective in 4–38% of patients with BM having 
various solid tumors [21]. Results are found to be limited on randomized trials on the effec-
tiveness of anticancer drugs, which hinder the development of a generally accepted strategy 
for effective SACT of BM, especially in patients without extracranial metastases and/or pro-
gression after BM local therapy (surgery, radiotherapy). Table 6 presents the effectiveness of 
chemotherapy in patients with brain metastases from NSCLC, melanoma, and breast cancer.
In a study performed by Franciosi et al. (1999), 107 patients with BM received a combination 
of cisplatin 100 mg/m2 (IV day 1) + etoposide 100 mg/m2 (IV on days 1, 3, and 5 or on days 4, 
6, and 8) every 21 days, was continued to a maximum of 6 cycles. The distribution according 
to the primary tumor site was non-small cell lung cancer in 43 (40%) patients, breast cancer 
in 56 patients (52%), and malignant melanoma in 8 (8%). Among the 107 patients with BM, 
7 BC patients achieved complete response (CR) (13%), 3 NSCLC patients achieved CR (7%), 
and none of the 8 MM patients achieved an objective response. The objective response rate 
(ORR) of the chemotherapy (CR + partial response (PR)) was recorded in 37.5% of patients 
with BC and in 30% of patients with NSCLC. The median survival was 7.5 months (range 
0–91.5+ months) for patients with NSCLC, 7.2 months (range 0–67 months) for patients with 
BC, and 4.0 months (range 0.5–11.2 months) for patients with MM. This chemotherapy regime 
is effective for patients with BM from BC and NSCLC [22].
Type of palliative treatment Indications
Surgical resection - BM localized (or most of it) in the brain critical structures (eyes, optical tracts, 
brainstem, etc.);
- Oligo-BM (1–2), especially when associated with extensive brain swelling;
- If morphological examination of CNS lesions is necessary.
Supportive care alone - Systemic disease progression after several types of palliative therapy in patients 
with poor performance status.
SACT: systemic anticancer therapy, WBRT: whole brain radiotherapy, SRS: stereotactic radiosurgery.
Table 5. Decision-making of palliative treatment options of BM patients.
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Chemotherapy regimen Primary tumor type Number of patients Response rate Median overall survival (months)
Cisplatin + etoposide NSCLC, breast cancer, melanoma Total 107 (100%):
NSCLC–43(40%),
BC–56 (52%),
MM–8 (8%)
Total 34 (32%):
NSCLC–13 (30%),
BC–21 (37.5%),
MM–0
NSCLC–7.5 (0–91,5+),
BC–7.2 (0–67),
MM–4.0 (0,5–11.2)
Etirinotecan pegol BC 32 5 (15.6%) All molecular types - 10 (7,8–15.7);
Triple negative – 7,6;
Lum A and В–12.2; HER2-type–16.1.
Temozolomide NSCLC, breast cancer, melanoma Total 157 (100%):
NSCLC–53(34%),
BC–51 (32%),
MM–53 (34%)
Total 10 (6%):
NSCLC–3 (6%),
BC–2 (4%),
MM–5 (9%)
NSCLC–5.7;
BC–n/a,
MM–3.3.
Gemcitabine + 
carboplatin
NSCLC 66 56 (29%) 7.6 (6.3–10.1)
Gemcitabine + paclitaxel 64 8.2 (4.6–10.5)
Carboplatin + paclitaxel 64 7.7 (6.1–10.2)
Cisplatin + gemcitabine BC 30 16 (53.3%) 10
18 All molecular types:
6 (33.4%);
Triple negative: 66.6%,
Lum A and В: 25%,
HER2-type: 12.5%
Median PFS:
All molecular types – 5.6 (2.4–8.8);
Triple negative – 7.4 (2.4–12.3);
Luml A and В: −3.6;
HER2-type: 5.
Carmustine + 
methotrexate
BC 48 11 (23%) All molecular types: 6.9 (4.2–10.7);
Her2/neu: overexpression/amplification (n = 8): 
14,1;
Her2/neu-negative: 5.9 (3,9–8.2).
Pemetrexed NSCLC 39 15 (38.4%) 10
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Chemotherapy regimen Primary tumor type Number of patients Response rate Median overall survival (months)
Pemetrexed + cisplatin NSCLC 43 18 (41.9%) 7.4 (5.8–9.6)
Capecitabine + lapatinib BC with Her2/neu: overexpression/
amplification
799 29.2% (18.5–42.7) 11.2 (8.9–14.1)
NSCLC: non-small cell lung cancer, BC: breast cancer, MM: malignant melanoma, Triple negative: ER-negative, PR-negative, Her2/neu-negative; Lum A: ER-positive 
and/or PR-positive, Her2/neu-negative; HER2-type: ER-negative, PR-negative, Her2/neu-overexpression/amplification; Lum В: ER-positive and/or PR-positive, Her2/neu-
overexpression/amplification, n/a: not applicable.
Table 6. The efficacy of systemic chemotherapy in patients with brain metastases.
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In open-label, multicentre, randomised phase 3 study (BEACON; BrEAst Cancer Outcomes 
with NKTR-102), was study the effectiveness of etirinotecan pegol 145 mg/m² (IV day 1 every 
3 weeks) monotherapy in 32 BC patients with BM previously treated with an anthracyclines, a 
taxanes, and capecitabine. In this study, there were no recorded cases of CR, partial response 
was detected only in 5 (15.6%), and 14 (43.8%) patients had disease progression. With a median 
follow-up of 21.1 months, the progression-free survival (PFS) for 32 patients was 3.1 months 
(range 1.8–4.0 months), and the median OS 10 months (range 7.8–15.7 months). The efficacy 
of etirinotecan pegol in BM patients depended on the BC molecular type and median OS was: 
16.1 months in HER2-type, 12.2 months in luminal A and B types, and 7.6 months in patients 
with triple negative BC. The results of the BEACON study recommend the etirinotecan pegol 
for treatment in BM patients with HER2-type and luminal breast cancer types [23].
Siena and co-workers (2010) reported on a nonrandomized multicenter phase II study of 157 
patients with cerebral metastases of NSCLC 53 (34%), BC 51 (32%), and melanoma 53 (34%) 
who received temozolomide 150 mg/m2 per day (oral administration for 1–7 and 15–21 days 
every 28 or 35 days). The BM complete response was recorded in one (<1%) patient with 
NSCLC. Among 157 patients, 9 (6%) had PR, and stabilization of disease (SD) was detected 
in 31 (20%) of 157 patients. The PFS was 66, 58, and 56 days for NSCLC, breast cancer, and 
melanoma BM patients, respectively. The median OS for patients with NSCLC was 172 days, 
melanoma was 100 days, and was not applicable in the breast cancer group. The results of this 
study indicate a low effectiveness of high dose-dense temozolomide regimen for the treat-
ment of brain metastases from NSCLC, BC, and melanoma [24].
At randomized phase 3 clinical trial comparing 3 chemotherapy regimens in 194 patients with 
clinically stable BM from NSCLC, all patients were randomized into 3 groups: group 1 (n = 66) 
received the gemcitabine 1000 mg/m2 (on days 1 and 8) + carboplatin AUC 5.5 (on day 1), 
group 2 (n = 64) received gemcitabine 1000 mg/m2 (on days 1 and 8) + paclitaxel 200 mg/m2 (on 
day 1), and group 3 (n = 64) received carboplatin AUC 5.5 (on day 1) + paclitaxel 225 mg/m2  
(on day 1) IV every 3 weeks, was continued to a maximum of 6 cycles. The study results 
showed the same clinical efficacy for all three regimens. Median OS was 7.6 months (range 
6.3–10.1 months) for patients from group 1, 8.2 months (range 4.6–10.5 months) for group 2, 
and 7.7 months (range 6.1–10.2 months) for group 3 [25].
Two studies evaluated the efficacy of BM patients from BC treatment with cisplatin + gem-
citabine chemotherapy regimen. Naskhletashvili and colleagues reported results of treatment 
in 30 patients with BC brain metastases who received cisplatin 50 mg/m2 (on days 1 and 
8) + gemcitabine 1000 mg/m2 (on days 1 and 8) IV every 3–4 weeks. ORR for chemotherapy 
was recorded in 6 (53.3%) patients, and the median OS was 10 months [26]. Similar results 
were obtained by Erten et al. [27]. In this study, 18 BC patients with BM who were treated 
with cisplatin 30 mg/m2 (on days 1 and 8) + gemcitabine 1000 mg/m2 (on days 1 and 8) IV 
every 21 days. The ORR depended on the primary tumor molecular type and was 33.4% for 
all BC molecular types, 66.6% for triple-negative BC, 25% for luminal types, and 12.5% for 
patients with HER2- type. The overall survival rates of these study patients have not been 
reported. Median PFS also depended on the type of breast cancer and was greatest in patients 
with triple-negative breast cancer at 7.4 months (range 2.4–12.3 months); in patients with 
HER2-type at 5 months, with luminal types at 3.6 and 5.6 months (range 2.6–8.8 months) for 
all breast cancer molecular types [27].
Cancer Management and Therapy66
Jacot and co-workers reported on 48 breast cancer patients treated with carmustine 100 mg/m2 
(on day 1) + methotrexate 600 mg/m2 (on days 1 and 15) IV of a 28-day cycle. Patients with 
Her2/neu overexpression and/or amplification received trastuzumab 4 mg/kg (on days 1 and 
15) IV during each cycle of chemotherapy. The ORR was detected in 11 (23%) patients. The 
PFS was 4.2 months (range 2.8–5.3 months), and the median OS at 6.9 months (range 4.2–10.7 
months) for all BC molecular type. The median OS was different in patients with the Her2/neu 
overexpression and/or amplification tumors (14.1 months) and without Her2/neu overexpres-
sion and/or amplification BC (5.9 months) [28].
The efficacy of pemetrexed in NSCLC patients with BM was evaluated in several studies. 
Bearz et al. (2009) reported about clinically significant efficacy monotherapy of pemetrexed 
500 mg/m2 IV (on day 1) every 3 weeks as a 2- or 3-line chemotherapy. ORR was detected in 15 
(38.4%) from 39 patients with BM from NSCLC, and median OS was 10 months. Barlesi et al. 
(2011) evaluated the efficacy of the regimen pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (IV 
on day 1) every 3 weeks for 6 cycles. The ORR was recorded in 18 (41.9%) of 43 patients with 
BM from NSCLC, and the median OS was 7.4 months (range 5.8–9.6 months). The concurrent 
administration of WBRT with chemotherapy pemetrexed + cisplatin significantly increases the 
treatment effectiveness according to the results obtained by Dinglin et al. (2013). The ORR of 
the pemetrexed + cisplatin + WBRT regimen was detected in 28 (68.3%) of 41 NSCLC patients 
with BM, and median OS was 12.6 months [29].
The efficacy of combination capecitabine and lapatinib for the treatment of Her2/neu overex-
pression on BC patients with BM has been investigated in several studies. A systematic review 
and meta-analysis of 12 studies, for total 799 patients with BM from Her2/neu-positive breast 
cancer, was show revealed ORR was 21.4% (range 11.7-35.9). After excluding from the analy-
sis patients who received lapatinib alone, the ORR was 29.2% (range 18.5–42.7). The median 
OS of patients with BM from Her2/neu-positive BC was 11.2 months (range 8.9–14.1 months), 
and PFS was 4.1 months (range 3.1–6.7 months) [30].
The targeted therapies and immunotherapies that have the significant efficacy for treatment 
on patients with BM from various malignant tumors are presented in Table 7.
Iuchi et al. [31] reported on 41 patients with BM from epidermal growth factor receptors (EGFR) 
mutant lung adenocarcinoma treated with gefitinib. Patients were assigned gefitinib 250 mg/
day until the disease progression or development of unacceptable toxicity. The ORR was 87.8%, 
and the median OS and PFR were 21.9 months (range 18.5–30.3 months) 14.5 months (range 
10.2–18.3 months), respectively [31].
Gerber and associates [32] presented the results of treatment on 110 patients with BM EGFR-
mutated lung adenocarcinoma. Depending on the treatment regimen, all patients were 
divided into 3 groups: group 1 (n = 63) patients who received erlotinib day until the disease 
progression or development of unacceptable toxicity, group 2 (n = 32) was treated only WBRT, 
group 3 (n = 15) was treated only SRS. The median OS of all 110 patients was 33 months: 
26 months in group 1 and 35 and 63 months in groups 2 and 3, respectively [32].
An open-label, single-arm, phase 2, multicenter study was performed to investigate the effi-
cacy of vemurafenib in 146 patients with BM from BRAFV600-mutated melanoma. Patients 
were divided into two cohorts: cohort 1 (n = 90) patients who had not previously received BM 
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local therapy (radiation therapy or surgery), and previous systemic therapy did not include 
BRAF or MEK inhibitors; cohort 2 (n = 6) patients with progression of melanoma BM after 
previous local therapy. ORR was 18% in both cohorts (16 and 10 patients in cohort 1 and 2, 
Name Primary tumor 
type
Number of  
patients
Response rate Median overall survival 
(months)
Gefitinib NSCLC 41 36 (87.8%) 21.9 (18.5–30.3)
Erlotinib 63 n/a 26
Vemurafenib MM cohort 1–90
cohort 2–56
16 (18%)
10 (18%)
8.9 (0.6–34.5)
9.6 (0.7–34.3)
Dabrafenib cohort 1–89
cohort 2–83
cohort 1
V600E–39%
V600 K–31%
cohort 2
V600E–7%
V600 K–22%
cohort 1
V600E–7.6;
V600K–3.7;
cohort 2
V600E–7.2;
V600 K–5.0;
Crizotinib NSCLC 20 3 (15%) 10.3
Ceritinib NSCLC 124 (ASCEND-1) 10* (36%) n/a
140 (ASCEND-2) 54 (38.6%) n/a
50 (ASCEND-3) 29 (58%) n/a
Alectinib NSCLC 136 (100%)
50* (37%)
86** (63%)
32* (64%)
37** (43%)
n/a
Bevacizumab + carboplatin + 
paclitaxel
67 42 (62.7%) 16
Trastuzumab BC 56 n/a 10.5 (8.3–17.7)
Lapatinib 30 n/a 21.4 (12.5–27.1)
Trastuzumab + lapatinib 28 n/a 25.9 (18.5–30.1)
Ipilimumab MM cohort А–51
cohort В–21
cohort А
9 (18%)
cohort В
1 (5%)
cohort А
7 (4.1–10.8)
cohort В
3.7 (1.6–7.3)
Ipilimumab + fotemustine MM 20 1 (5%) 12.7 (2.7–22.7)
Pembrolizumab NSCLC, MM 18
18
6 (33%)
4 (22%)
7.7
n/a
n/a, not applicable.*Patients with measurable target brain lesions.
**Patients without measurable target brain lesions.
Table 7. The efficacy targeted therapy and immunotherapy in patients with brain metastasis.
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respectively). The PFS was 3.7 months (range 0.03–33.4 months) in cohort 1 and 4.0 months 
(range 0.3–27.4 months) in cohort 2. The median OS was 8.9 months (range 0.6–34.5 months) 
and 9.6 months (range 0.7–34.3 months) in cohort 1 and 2, respectively [33].
An open-label, phase 2, multicenter study (BREAK-MB) was evaluated to observe the effec-
tiveness of oral administration of dabrafenib 150 mg twice daily in 172 patients with brain 
parenchyma metastases from melanoma with a mutation of BRAF V600E (139 patients) and 
V600E (33 patients). Patients were divided into two cohorts: cohort 1 (n = 89) patients who 
had not previously received BM local therapy (radiotherapy or surgery), cohort 2 (n = 83) 
patients with intracranial progression of melanoma after previous BM local therapy. The 
ORR in cohort 1 was 39% and 31% in patients with mutations V600E and V600K, respec-
tively, and in cohort 2 in 7% of patients with mutation V600E and 22% with mutation 
V600K. The median OS in patients with the V600E mutation was 7.6 and 7.2 months, and 
3.7 and 5.0 months in patients with V600K mutation in cohort 1 and 2, respectively. The PFS 
was 3.7 months in patients with mutations BRAF V600E and V600K in cohort 1 and 2, respec-
tively, and 1.8 months in patients with BRAF V600K mutation in cohort 1, and 3.8 months 
in patients with BRAF V600K mutation in cohort 2 [34]. Xing P. and associates (2016) pre-
sented the results of crizotinib treatment on 20 advanced ALK-rearranged NSCLC patients 
with baseline brain metastases in Chinese population. The median OS of  patients was 10,3 
months and PFS was 21,2 months [35].
The efficacy of ceritinib for the treatment of BM in patients with ALK-positive NSCLC was 
evaluated in the ASCEND-1, ASCEND-2, and ASCEND-3 trials. In the ASCEND-1 study, 124 
patients with ALK-positive NSCLC were diagnosed with BM, 98 of the 124 patients had previ-
ously received ALK (crizotinib) inhibitor therapy prior to progression, and 26 patients with-
out previously ALK inhibitors treatment. Only 14 patients (10 patients had received crizotinib 
before and 4 had not received ALK inhibitors before) had investigator-assessed brain lesions 
selected as target lesions at baseline. In seven of them (four patients after previous therapy 
with ALK inhibitors and three without previous therapy) was detected PR and in three 
patients discovered SD (all after previous crizotinib therapy). The PFS was 6.9 months (range 
5.4–8.4 months) for all patients or 6.7 months (range 4.9–8.4 months) for patients previously 
treated with ALK inhibitors and 8.3 months (range 4.6–not applicable) for patients who have 
not previously received ALK inhibitors [36] .
Crino and co-workers [37] reported a single-arm, open-label, multicenter, phase 2 study 
of ceritinib in a heavily pretreated patient population with ALK-rearranged NSCLC 
(ASCEND-2) in 140 patients who received at least two lines of therapy including platinum-
based chemotherapy and crizotinib. The ORR was 38.6% (range 30.5%–47.2). The median 
of follow-up time 8.8 months (range, 0.1–19.4 months) and the median PFS was 5.7 months 
(range 5.4–7.6 months) [37].
In ASCEND-3 trial, efficacy of ceritinib was investigated in 124 ALK-positive NSCLC patients 
who had not previously received therapy with ALK inhibitors. Among 124 patients included 
in this study, 50 patients (40%) had BM, and radiation was performed on 27 (54%) patients for 
brain metastatic lesions. The median PFS was 10.8 months (range 7.3–not available), and ORR 
was detected in 27 (54%) patients [38].
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Gadgeel and assistants analyzed the results of two studies (NP28761 and NP28673) to inves-
tigate the efficacy and safety of the use of alectinib for treating patients with BM from ALK-
positive NSCLC with disease progression after previous treatment with crizotinib. Measurable 
target brain lesions were detected in 50 (37%) patients and in 86 (63%)—without measurable 
target brain lesions. The disease control rate (DCR) was detected in 32 (64%) patients with 
measurable target brain lesions (PR = 22%) and in 37 (43%) patients without measurable target 
brain lesions (PR = 27%). In patients who underwent radiation therapy of BM (n = 95) before 
started alectinib therapy intracranial response rate (ICRR) was 35.8% versus 58.5% in patients 
(n = 41) who did not receive previously radiation therapy [39].
At phase II prospective, noncomparative BRAIN study investigated efficacy and safety of 
combination bevacizumab (15 mg/kg) + carboplatin (AUC 6) + paclitaxel (200 mg/m2) IV every 
3 weeks as the first line of treatment of non-squamous NSCLC patients (n = 67) with asymp-
tomatic, previously untreated BM. PR and SD of intracranial metastases was recorded in 42 
(62.7%) and 18 (26.9%), respectively. Median PFS was 6.7 months. (5.7–7.1), and the median 
OS was 16 months [40].
In the retrospective multicenter study, Yap and co-workers [41] evaluated the efficacy of anti-
Her2/neu therapy in patients with BM from Her2/neu overexpression BC. Among 280 patients 
with BM Her2/neu-positive BC, 260 (92.9%) patients underwent radiation therapy, 160 (57.1%) 
patients underwent chemotherapy, and 114 (40.7%) anti-Her2/neu therapy. Of the 114 patients 
receiving anti-Her2/neu therapy, 56 (49.1%) patients receive trastuzumab, 30 (26.3%)—lapa-
tinib and 28 (24.6%) trastuzumab plus lapatinib combination. The median OS was significantly 
higher in patients receiving combined anti-Her2/neu therapy and was 10.5 months (range 8.3–
17.7 months) in the trastuzumab group, 21.4 months (range 12.5–27.1 months) in the lapatinib 
group, and 25.9 months (range 18.5–30.1 months) in patients from the trastuzumab + lapatinib 
group [41].
An open-label, phase 2 trial investigated efficacy of ipilimumab for the treatment of patients 
with BM from melanoma. A total of 72 melanoma patients with BM were divided into 2 cohorts: 
cohort A (n = 51)—patients with asymptomatic BM, cohort B (n = 21)—patients with symptom-
atic BM and received glucocorticoids. All patients received ipilimumab at 10 mg/kg IV every 
3 weeks for a total of 4 cycles. The DCR was 18% in cohort A and 5% in cohort B. Overall 
survival for 1 year was 31% and 19% with a median OS 7 months (range 4.1–10.8 months) and 
3.7 months (range 1.6–7.3 months) in the cohort A and B, respectively [42].
In the NIBIT-M1 study Di Giacomo and co-workers [43] reported on 20 patients with asymp-
tomatic BM from melanoma who received combined systemic therapy of ipilimumab (10 mg/kg 
IV every 3 weeks for a total of 4 injections) and fotemustine (100 mg/m2 IV weekly total 3 injec-
tions). Maintenance therapy was carried out according to the regiment: fotemustine every 
3 weeks from 9 weeks of therapy and ipilimumab every 12 weeks from 24 weeks from the 
onset of systemic therapy to disease progression or patient failure, or to the occurrence of 
excessive toxicity. Maintenance therapy was carried out according to the regiment: fotemus-
tine every 3 weeks from 9 weeks of therapy and ipilimumab every 12 weeks from 24 weeks 
from the onset of systemic therapy to disease progression or patient failure, or to the occur-
rence of excessive toxicity. Seven patients (35%) before systemic treatment were radiotherapy. 
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The ORR was 5% at an immunological response rate was 50%. With median follow-up of 
39.9 months, the 3-year OS was 27.8%, and the median OS was 12.7 months.
Goldberg et al. [44] in non-randomized, open-label, phase 2 trial was investigated effectiveness 
of pembolizumab in 36 patients with asymptomatic BM from NSCLC (n = 18) and melanoma 
(n = 18). The PD-L1 expression in primary tumor was detected in patients with NSCLC only. 
All patients received pembolizumab 10 mg/kg IV every 2 weeks before disease progression. 
The ICRR was 33% for NSCLC and 22% for melanoma. The median follow-up was 11.6 months 
(range 8.5–13.9 months) and median OS was not achieved (NA) in the patients with mela-
noma BM. The median follow-up was 6.8 months (range 3.1–7.8 months) and median OS was 
7.7 months (range 3,5–ND) in the NSCLC patients with BM [44].
6. Conclusions
In recent decades, significant progress has been made in diagnosing, predicting, and treatment 
of patients with BM of various malignant tumors. Nevertheless, the successes achieved are not 
sufficient, since the overall survival rates of patients remain low. Further studies of the mecha-
nisms of metastasis of malignant tumors in the brain can serve as a basis for the development 
of methods for the prevention of BM, and the study of the role of BBB in the development of 
resistance to systemic therapy will help develop methods that overcome this natural barrier 
and increase the effectiveness of antitumor drugs. Applying a multidisciplinary approach to 
developing patient treatment, tactics using the current flow forecast scales will lead to a more 
valid appointment of radiation therapy, surgery, systemic antitumor and symptomatic therapy 
to preserve the neurological and neurocognitive function, and the quality of life of patients.
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